We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Renalytix Plc | LSE:RENX | London | Ordinary Share | GB00BYWL4Y04 | ORD 0.25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-1.50 | -4.29% | 33.50 | 32.00 | 35.00 | 35.00 | 33.50 | 35.00 | 92,711 | 16:26:48 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Services, Nec | 3.4M | -46.22M | -0.4626 | -0.72 | 33.48M |
Date | Subject | Author | Discuss |
---|---|---|---|
22/7/2020 07:57 | This video shows very succinctly why PYC could be worth MULTIPLES of 100p Tempus is a $5bn startup targeting 'Personalised Precision Oncology' If they are serious (they certainly sound like it) they or others in this huge emerging field will have to snap up a Company with the specialist knowledge / Virtual Tumour model and relationships Physiomics have built over 20 years IMO Why PYC could be the RENX of Cancer AI | the stigologist | |
22/7/2020 07:56 | This video shows very succinctly why PYC could be worth MULTIPLES of 100p Tempus is a $5bn startup targeting 'Personalised Precision Oncology' If they are serious (they certainly sound like it) they or others in this huge emerging field will have to snap up a Company with the specialist knowledge / Virtual Tumour model and relationships Physiomics have built over 20 years IMO Why PYC could be the RENX of Cancer AI | the stigologist | |
22/7/2020 07:35 | With the closing of the global offering, I am interested to see if Renalytix increase their 'initial' equity interest in Kantaro Bioscience. Given the relationship, I am also interested to see whether the approved test dovetails with with Mount Sinai's efforts in developing AI to help diagnose and treat Covid-19, which make sense, or indeed whether Renalytix extends their reach to COVID-19 AI related diagnostics - Mount Sinai Center Developing AI to Help Diagnose, Treat Covid-19 COVID Informatics Center aims to help the hospital network make more efficient use of its resources By Elliot M. Kass July 16, 2020 New York's Mount Sinai gets Microsoft grant for COVID-19 data center: Laura Dyrda (Twitter) Tuesday, June 9th, 2020 New York City-based Mount Sinai Health System received a grant for an undisclosed amount from Microsoft for its new COVID-19 data science center. Four things to know: 1. Microsoft AI for Health awarded the Mount Sinai COVID Informatics Center a grant and cloud resources to accelerate discovery, translation and digital tool implementation. 2. The new center focuses on developing tools using artificial intelligence that will enhance evidence-based medicine related to COVID-19 treatment. It will use Microsoft Azure cloud computing for complex patient data storage. 3. Mount Sinai aims to rapidly develop digital health products with real-time predictive and preventive capabilities at the new center, which recently launched a study to monitor the biometrics of healthcare workers using Apple watches. These efforts will help the system understand the stress and anxiety healthcare works face on the front lines. 4. The grant also will support the health system develop an infrastructure to improve patient outcomes after the pandemic. | wan | |
22/7/2020 06:13 | hxxps://stocktwits.c This one is good but no page yet. | mr roper | |
22/7/2020 05:32 | Agree good to have an up finish 👍🏼 Does any one know which share chat sites are the most active in the Us? Trying to find some forums over there to monitor local discussions | 2theduke | |
21/7/2020 21:26 | Agree, however they initially stated that they would submit it for FDA approval by the end of May & it ended up being 17th June, which I suspect was partly tactical. Let’s see! Ps. Nice to see us close at $14 on NASDAQ, volume has been decent so far too. | 74tom | |
21/7/2020 21:10 | Can’t imagine you get a choice on timing that Rns . But let’s hope you’re right | 2theduke | |
21/7/2020 16:48 | Global offering now closed, I’d say the decks are now clear for newsflow - they clearly weren’t going to announce the antibody approval in the midst of the IPO... | 74tom | |
21/7/2020 15:35 | not in their hands - waiting for regulatory approval? | nimbo1 | |
21/7/2020 15:31 | They’re getting a bit late on the anti body test update, given kantaro still states a lunch in July... | 2theduke | |
21/7/2020 14:20 | There will be plenty of pi's selling because it didn't double day one. They need to execute from an operational perspective - as and when they do share price will increase dramatically I would have thought. We are now tied to the nasdaq price and other than the insti's who purchased shares over there no other investors have heard of renx yet. Im sure when Stifel resume coverage and put out an investment note / renx release their first news on nasdaq you'll see interest pick up. also the share price has travelled quite a long way relatively quickly - you always get periods of distribution after such times...especially after raising money! The key thing is they have their money so the potential to be a great success is now in their hands : ) | nimbo1 | |
21/7/2020 14:11 | It baffles me that anyone would want to sell right now, you can bet your bottom dollar that they’ll have strong newsflow lined up for the next few months to support the NASDAQ listing. I’ve added some more today, looking forward to the ride :) | 74tom | |
21/7/2020 13:26 | For newbies to Physiomics (PYC) it is worth reading the 'Plain English Summary' on the Government NIHR (National Institute for Health Research) website detailing what their Precision Personalised Oncology Tool is about. This is just their 'first' tool aimed at Prostate Cancer. Expect more in future with the ultimate goal being a complete 'Cancer Decision Support System' tool to help front line clinicians decide best treatment regimens for Patients (ideally based on their individual genotype / phenotype) | the stigologist | |
21/7/2020 09:47 | UK Govt has funded PYC VT model to tune of £0.5m so far Imagine if UK Govt had invested £0.5m in likes of AVCT GDR ODX NCYT. It's not just the money but validation which speaks volumes | the stigologist | |
20/7/2020 13:18 | Deep Dive Into Big Pharma AI Productivity: One Study Shaking The Pharmaceutical Industry Very interesting on how early stage this move to AI is in Pharma and how slow moving Big Pharma is How they are very slow to take on board outside technology (a great feather in PYC cap they have got into Merck KGaA and others) Merck KGaA clearly leading edge and punching well above their weight in AI adoption Another validation of PYC Getting another Large Pharma on board could be start of a domino effect/tsunami of contracts/revenue growth over coming years | the stigologist | |
20/7/2020 11:57 | Toffeeman - True, basic error on my part! | hpcg | |
20/7/2020 10:39 | Another 4 from my listening - but would need to listen again to double check. | nimbo1 | |
20/7/2020 10:22 | Is that another 3 or another 4 Nimbo? | melody9999 | |
20/7/2020 09:49 | The UK research (on research tree) has revenue predictions of $24 million for this full year just entered - that depends on when Mount Sinai goes commercial during the next few months of course but the revenue is just anticipated from that 1 installation. In the US IPO presentation they state they expect to have another 4 up and running within 12 months. So theoretically annualised revenue could be c.$125 million when all of those are up and running. Clearly at the moment pre revenue a lot is taken on trust and you have to buy into the story and execution operationally - however if the above happens you'll see a $1billion market cap here within 12 months...and they'll still only be scratching the surface of the ultimate market and potential. Everything normally takes longer than expected! Mount Sinai coming into the fund raise was very important ref confidence from my own perspective. | nimbo1 | |
20/7/2020 09:33 | Need to think of the current price as ex-Verici. | toffeeman | |
20/7/2020 08:52 | I've bought more here, though at the top end of the spread. Logical resting place, but not factoring in the US investors are simply a lot more bullish on growth than UK investors. | hpcg | |
20/7/2020 08:26 | I’m a buyer at this level | volsung | |
20/7/2020 08:22 | my sense is that this is probably the wrong time to be selling any. the share price is at the NASDAQ placing price which should act as a floor; US buyers should now start to take up stock and we can expect further newsflow on KidneyIntel; in addition the RNS on 20/5 referred to the COVID-19 scaled kit production starting in July to enable clinical laboratories to conduct 10M tests per month. | melody9999 | |
20/7/2020 08:09 | If by magic the price had opened this morning at £50, you would have PI’s that would buy shares, the same goes for if they opened at 50p, a number would sell... shares price behaviour is a fascinating insight into human psychology! | 74tom | |
20/7/2020 07:45 | Almost at the placing price - makes sense! I’ll probably buy some more but now have to decide where. Coverage in the US not good yet - no stocktwits page for example (their equivalent of advfn). Certainly some selling by pi’s going on - probably the ones that pushed the price to 625! | nimbo1 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions